Companies
8-K ↗8-K ↗
KRYS
Krystal Biotech, Inc.
Krystal Biotech develops gene therapies using a proprietary herpes simplex virus (HSV-1) based vector platform, primarily focused on genetic skin diseases. The company's lead product, VYJUVEK, was approved by the FDA in May 2023 and the European Commission in April 2025 for treating dystrophic epidermolysis bullosa (DEB), and it is now in the commercialization stage across the United States, European Union, Japan, and other markets.
$262.26+54.38%1Y
KRYS · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Dystrophic Epidermolysis Bullosa
Phase 3DEB - Dystrophic Epidermolysis Bullosa
Phase 3Recessive Dystrophic Epidermolysis Bullosa
Phase 3Dominant Dystrophic Epidermolysis Bullosa
Phase 2Lung Cancer, Non-small Cell
Phase 2Lung Cancer Metastatic
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
Phase 2Lung Cancer, Non-small Cell
Phase 2Lung Cancer Metastatic
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
Phase 2Lung Cancer Metastatic
Phase 2Lung Cancer, Non-small Cell
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
Phase 2Cancer
Phase 2Melanoma Stage III
Phase 2Melanoma Stage IV
Phase 2Cutaneous Melanoma
Phase 2Neurotrophic Keratitis
Phase 2Cancer
Phase 2Melanoma Stage III
Phase 2Melanoma Stage IV
Phase 2Cutaneous Melanoma
Phase 2Lung Cancer, Non-small Cell
Phase 2Lung Cancer Metastatic
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
UnknownIndication pending review
Catalyst Calendar
Past (2)
AUG 28
InterimKB301
“phase 1 (PEARL-1) positive interim safety and efficacy results for KB301 in the treatment of lateral canthal lines and dynamic wrinkles of the décolleté”
AUG 28
Conf.KB301
“the Company and Krystal Biotech, Inc. would host a conference call and webcast at 4:30 p.m. ET on August 28, 2024, to discuss the PEARL-1 Cohort 3 and Cohort 4 interim results”